Stocks · News reference
Kazia Therapeutics Reports New Preclinical And Translational Data Showing Lead Asset Paxalisib Reduced Tumor Burden By 52% In MSS/pMMR Colorectal Cancer
Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further ReductionPaxalisib Was Well Tolerated as Monotherapy and
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Kazia Therapeutics Announces New Preclinical Data Showing Safety, Anti-Tumor Activity Of Paxalisib In HR+/HER2- Breast Cancer; First Patient Expected By Year-End 2026 And Full Enrollment By End Of 2027
Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor ActivityThree-Arm Expansion of the Ongoing TNBC Trial Will Evaluate Paxalisib
Kazia Therapeutics Announces Pricing Of $40M Underwritten Offering Of ADSs And Pre-Funded Warrants